Prashant B Nigade1, Jayasagar Gundu2, K Sreedhara Pai3, Kumar V S Nemmani4. 1. Department of Drug Metabolism and Pharmacokinetics, Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Pune, 412 115, India. prashantnigade@lupin.com. 2. Department of Drug Metabolism and Pharmacokinetics, Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Pune, 412 115, India. 3. Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India. 4. Department of Pharmacology, Lupin Limited (Research Park), Pune, India.
Abstract
BACKGROUND: Predicting target site drug concentrations is of key importance for rank ordering compounds before proceeding to chronic pharmacodynamic models. We propose generic tumor-specific correlation-based regression equations to predict tumor-to-plasma ratios (tumor-Kps) in slow- and fast-growing xenograft mouse models. METHODS: Disposition of 14 basic small molecules was investigated extensively in mouse plasma, tissues and tumors after a single oral dose administration. Linear correlation was assessed and compared between tumor-Kp and normal tissue-to-plasma ratio (tissue-Kps) separately for each tumor xenograft. The developed regression equations were validated by leave-one-out cross-validation (LOOCV) method. RESULT: Both slow- and fast-growing tumor-Kps showed good correlation (r 2 ≥ 0.7) with majority of the normal tissue-Kps. Substantial difference was observed in the slopes of developed equations between two xenografts, which was in line with observed difference in tumor distribution. The linear correlations between tumor-Kp and skin- or spleen-Kp were within the acceptable statistical criteria (LOOCV) across xenografts and the class of compounds evaluated. Since > 70% of tumor-Kps from the test data sets were predicted within a factor of twofold for both slow- and fast-growing xenograft mouse models, the results validate the applicability of the developed equations across xenografts. CONCLUSION: Tumor-specific correlation-based regression equations were developed and their applicability was adequately validated across xenografts. These equations could be successfully translated to predict tumor concentrations in order to preclude experimental tumor-Kp determination.
BACKGROUND: Predicting target site drug concentrations is of key importance for rank ordering compounds before proceeding to chronic pharmacodynamic models. We propose generic tumor-specific correlation-based regression equations to predict tumor-to-plasma ratios (tumor-Kps) in slow- and fast-growing xenograft mouse models. METHODS: Disposition of 14 basic small molecules was investigated extensively in mouse plasma, tissues and tumors after a single oral dose administration. Linear correlation was assessed and compared between tumor-Kp and normal tissue-to-plasma ratio (tissue-Kps) separately for each tumor xenograft. The developed regression equations were validated by leave-one-out cross-validation (LOOCV) method. RESULT: Both slow- and fast-growing tumor-Kps showed good correlation (r 2 ≥ 0.7) with majority of the normal tissue-Kps. Substantial difference was observed in the slopes of developed equations between two xenografts, which was in line with observed difference in tumor distribution. The linear correlations between tumor-Kp and skin- or spleen-Kp were within the acceptable statistical criteria (LOOCV) across xenografts and the class of compounds evaluated. Since > 70% of tumor-Kps from the test data sets were predicted within a factor of twofold for both slow- and fast-growing xenograft mouse models, the results validate the applicability of the developed equations across xenografts. CONCLUSION:Tumor-specific correlation-based regression equations were developed and their applicability was adequately validated across xenografts. These equations could be successfully translated to predict tumor concentrations in order to preclude experimental tumor-Kp determination.
Authors: Helen Graham; Mike Walker; Owen Jones; James Yates; Aleksandra Galetin; Leon Aarons Journal: J Pharm Pharmacol Date: 2011-12-21 Impact factor: 3.765
Authors: Prashant B Nigade; Jayasagar Gundu; K Sreedhara Pai; Kumar V S Nemmani Journal: Eur J Drug Metab Pharmacokinet Date: 2017-10 Impact factor: 2.441
Authors: Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson Journal: Drug Metab Dispos Date: 2013-02-01 Impact factor: 3.922